STOCKS TELEGRAPH

Tag: NASDAQ:ARAV

  • Aravive Inc. (ARAV) stock surged in the premarket trading hours; here’s why

    Aravive Inc. (ARAV) shares were rising in the premarket trading session, as at the last check the share price of ARAV stock had increased by 25.94% to $6.70. ARAV stock had gained 0.95% while previously closing the trading session at $5.32. The ARAV stock volume traded 0.17 million shares, which was higher than the three-month average volume of 155.29K shares within the past 90 days. In the past year up to date, ARAV stock shed -62.85%, and in the past week however, it moved up by 2.11%. In the past three and six months, the stock went down by -21.88% and shed -15.42% respectively. Furthermore, Aravive Inc. is currently valued in the market at $108.42 million and has 18.07 million outstanding shares.

    What you need to know about Aravive Inc.

    Aravive Inc. is a clinical stage biopharmaceutical company that specifically focuses on discovering and designing treatments for unmet needs of doctors and patients with life-threatening diseases. The company specifically produces treatments designed to halt life-threatening diseases which includes their lead candidate product for the treatment of platinum0resistant recurrent ovarian cancer. This candidate is known as AVB-500 which is a decoy of protein for GAS6-AXL signaling pathway targeting. AVB-500 is in the phase Ib/II of a clinical trial for the ovarian cancer study as well as treatment of negative breast, uterine, pancreatic, lung, urothelial cancers and renal cell carcinoma.

    Another candidate for the blocking of activation of GAS6-AXL signaling pathway is known as AVB-S6 which is a soluble FC fucion protein. ARAV stock has partnered with WuXI Biologics in a strategic collaboration agreement for the development of high-affinity bispecfic antibodies that target fibrosis in patients as well as cancer. The company also partnered with 3D Medicines Inc. in a license agreement for the production of the sole drug substance for the treatment of human oncological diseases in mainland China as well as Hong Kong, Taiwan, and Macau.

    The company was previously registered as Versartis Inc. until October 2019 and is established in Houstan, Texas.

    Positive results with no unexpected finding in the AVB-500 Phase 1b trial

    The AVB-500 had underwent the phase1b/2 study and has recently announced that the phase 1b portion has its results arrived. The results showcase a positive initial interim data the details of which specify the combination of 15mg/kg of AVB-500 dosage with cabozantinib for patients that have advanced stage kidney cancer or otherwise termed as clear cell renal cell carcinoma. The study showcases that AVB-500 had no adverse effects intolerable for the three evaluable patients under observation and have found no unexpected findings.

    The next step of the company is to expand the dosing by registering three more patients for the evaluation of potential of initiating the phase 2 portion of this study. To be further sure, the company will also administer higher doses of AVB-500 for Phase 1b to ensure expected results and reduce deviations from favorable results.

  • Aravive Inc. (ARAV) stock price going up today, here is what happened

    Aravive Inc. (ARAV) stock price remained unchanged on Tuesday, March 16, 2021, but it gained 8.13% in the after-hours trading as ARAV Stock announced its financial results for the fourth quarter and full-year ended December 31, 2020, around 4 pm on Tuesday.

    Financial Highlights

    • ARAV Revenue for the three months and twelve months ended December 31, 2020, was $5.7 million for both periods.
    • It spent $9.7 million on operating expenses in the reported quarter and $36.5 million for the whole year
    • Aravive reported a net loss of $4.0 million, $0.25 per share for the reported quarter and $30.5 million, $1.93 per share for the full year 2020.
    • ARAV had cash and cash equivalents of $60.5 million on December 31, 2021, compared to $65.1 million as of December 31, 2019.

    Corporate updates

    • FDA guided ARAV on a registrational Phase 3 trial design for AVB-500 in PROC and initiated the trial during the first quarter of 2021. The global randomized trial will enrol 300-500 patients and will evaluate the efficacy and tolerability of AVB-500 at a dose of 15 mg/kg in combination with paclitaxel vs paclitaxel monotherapy.
    • Aravive dosed its first patient in its Phase 1b/2 trial of AVB-500 in ccRCC during the first quarter of 2021. The Phase 1b portion of the trial is expected to enrol up to 18 patients in three dosing arms (15 mg/kg, 20 mg/kg and 25 mg/kg) to evaluate tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AVB-500 in combination with cabozantinib. Aravive expects to report topline data from the Phase 1b portion of the trial in the second half of 2021.
    • Aravive signed a license agreement with 3D Medicines Inc. for the development and commercialization of AVB-500 in China Hong Kong, Macau, and Taiwan. ARAV will get $12 million and is eligible to receive up to $207 million in development and commercial milestone payments and also a percentage form net sales of AVB-500 in Greater China.

    Participation in Society of Gynecologic Oncology Annual Meeting

    On March 12, 2021, ARAV announced that it is going to present updated data from its Phase 1b trial evaluating AVB-500 in platinum-resistant ovarian cancer (PROC) at the 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. the meeting is scheduled to held virtually on March 19-25, 2021.

    Participation in virtual investors conferences

    Aravive, Inc. participated and conducted meeting virtually at the H.C. Wainwright Global Life Sciences Conference which took place on March 9-10, 2021.

    Aravive stock is also going to participate virtually in the Oppenheimer 31st Annual Healthcare Conference scheduled for Thursday, March 18, 2021, at 8:00 a.m. ET.

    About ARAV

    Aravive, Inc. was founded in 2008 and is based in Houston, United States. ARAV is a clinical-stage oncology company developing transformative therapeutics designed to stop the advancement of life-threatening diseases.